首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

EXPERT OPINION ON BIOLOGICAL THERAPY
ISSN：1471-2598

EXPERT OPINION ON BIOLOGICAL THERAPY

EXPERT OPIN BIOL TH
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：一般,3-8周
新锐分区：医学3区
年发文量：123
影响因子：4
JCR分区：Q2

基本信息

生物疗法专家意见（1471-2598; 1744-7682）是一个MEDLINE索引，国际期刊发表生物治疗各个方面的同行评审研究。每篇文章的结构都包含作者自己的专家意见，这些意见涉及主题对研究和临床实践的影响以及未来发展的范围。受众包括医疗保健和生物制药行业的科学家和管理人员，以及其他密切参与开发和生物疗法在人类疾病治疗中的应用。该杂志欢迎：综述，涵盖治疗性抗体和疫苗，肽和蛋白质，基因疗法和基因转移技术，基于细胞的疗法和再生医学药物评估回顾特定生物制剂的临床数据原创研究论文，报告生物制剂的临床研究结果和基于生物疗法的研究，与临床实践有很强的联系。每一篇综述的全面报道都由独特的专家收藏格式补充，包括以下部分：专家意见-对文章中数据的个人观点，对未来可能重要的发展的讨论，以及随着进一步研究产生更详细的结果而可能变得令人兴奋的研究途径;文章亮点-作者最关键点的执行摘要。
1471-2598SCIE/Scopus收录
4
点击查看最新影响趋势>
3.9
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
3区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY
SCIE
Q2
50/177
学科：MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
Q2
62/195
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY
SCIE
Q3
96/177
学科：MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
Q3
102/195
75
123
点击查看年发文量趋势图>
3%较易一般,3-8周-医学-生物工程与应用微生物
2.5%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
26.83%11.25%0.59%
CiteScore：7.60
SJR：1.150
SNIP：0.885
学科类别分区排名百分位
大类：Biochemistry, Genetics and Molecular Biology
小类：Clinical Biochemistry
Q1
24 / 121
大类：Biochemistry, Genetics and Molecular Biology
小类：Pharmacology
Q1
71 / 321
大类：Biochemistry, Genetics and Molecular Biology
小类：Drug Discovery
Q2
42 / 156

期刊高被引文献

Complement inhibition as a therapeutic strategy in retinal disorders
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1575358
A vaccine against Alzheimer`s disease: anything left but faith?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1554646
Stem cell therapies for wound healing
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1596257
B cell depletion in the treatment of multiple sclerosis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1568407
Inflammatory cytokines: from discoveries to therapies in IBD
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1652267
Etanercept biosimilar SB-4
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1566456
Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1554053
Tocilizumab for the treatment of adult-onset Still’s disease
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1590334
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1685976
An update on therapies for the treatment of diabetes-induced osteoporosis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1618266
Current and emerging biologics for the treatment of hereditary angioedema
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1595581
Biosimilars for the treatment of psoriasis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1636963
Immunotherapeutic approaches in nasopharyngeal carcinoma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1650910
An update on immunotherapy options for urothelial cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1667975
Facing the future: challenges and opportunities in adoptive T cell therapy in cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1608179
IL-17 inhibition in axial spondyloarthritis: current and future perspectives
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1605352
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1571580
Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1651288
Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1575359
Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1707800
NK cell-based therapeutics for lung cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1688298
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1561852
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1644316
iNK-CD64/16A cells: a promising approach for ADCC?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1667974
Moxetumomab pasudotox for the treatment of hairy cell leukemia
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1614558
Endogenous lung stem cells for lung regeneration
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1596256
Pembrolizumab for the treatment of diffuse large B-cell lymphoma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1659777
Immune checkpoint inhibition for the treatment of renal cell carcinoma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1677601
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1610380
Defining the immunogram of breast cancer: a focus on clinical trials
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1598372
RPGR gene therapy presents challenges in cloning the coding sequence
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1680635
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1582635
Mesenchymal stromal cells for ocular surface repair
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1607836
Towards personalized treatment in atopic dermatitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1583204
Curcumin: footprints on cardiac tissue engineering
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1650912
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1623875
Histological healing: should it be considered as a new outcome for ulcerative colitis?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1701652
Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1689953
Candidate vaccines for human Rift Valley fever
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1662784
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1656715
Nivolumab for the treatment of unresectable pleural mesothelioma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1703945
The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1566455
Biological therapy of autoimmune blistering diseases
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1559291
An overview of tolerogenic immunotherapies based on plant-made antigens
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1597048
Clinical development of CT-P6 in HER2 positive breast cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1665019
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1702020
Is there room for immunomodulators in ulcerative colitis?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1708896
Special considerations for biologic medications in pediatric ulcerative colitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1685492
Bioengineering and regeneration of gastrointestinal tissue: where are we now and what comes next?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1595579
Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1673725

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

AAPS Journal封面

AAPS Journal

学科领域：医学
影响因子：3.7
中科院分区： 3区
AAPS PHARMSCITECH封面

AAPS PHARMSCITECH

学科领域：医学
影响因子：4
中科院分区： 3区
Academic Pediatrics封面

Academic Pediatrics

学科领域：医学
影响因子：2.8
中科院分区： 3区
ACTA ANAESTHESIOLOGICA SCANDINAVICA封面

ACTA ANAESTHESIOLOGICA SCANDINAVICA

学科领域：医学
影响因子：2
中科院分区： 3区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学3区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
3区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学3区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物
3区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
4区
否
是
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学3区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物
2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
3区
否
是